Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma

Inclusion Criteria: * Patient is age 18 years or older * Patient is diagnosed with non-resectable cholangiocarcinoma, as determined by CT within 30 days of enrollment and CT shows Bismuth Tumor Stage as: IIIa, IIIb, IV (Bismuth tumor stage I and II are not eligible to participate) * Patients must have adequate organ and marrow function as defined below: * Patient's INR ≤ 2 within 30 days of treatment * Patient's platelets \> 50,000/cmm within 30 days of treatment * Patient's Absolute Neutrophil Count (ANC) \> 1,500/cmm within 30 days of treatment * Patient's creatinine ≤ 3 mg/dL within 30 days of treatment * Patient has the ability to understand and the willingness to comply with the study procedures and provide written informed consent to participate in the study Exclusion Criteria: * Patient was diagnosed with cholangiocarcinoma more than 3 months ago * Patient has any metastatic disease * Patient has acute porphyria * Subjects exhibiting neurologic or cutaneous symptoms will undergo urinary delta-aminolevulinic acid and porphobilinogen dosage tests to determine severity. * Patient is pregnant (Women of child bearing age must have a negative pregnancy test prior to registration and must agree to use adequate contraception during study therapy) * Patient has a concurrent non solid malignancy